SciBX
Science-Business eXchange

THE DISTILLERY

This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
Induced pluripotent stem (iPS) cell–derived, chimeric antigen receptor (CAR)-expressing T cells for immunotherapy	iPS cell–derived, CAR-expressing T cells could be used for immunotherapy in patients when suitable autologous or allogeneic T cells are unavailable. In peripheral blood T lymphocytes, viral vector–mediated expression of four factors reprogrammed the cells into iPS cells. These iPS cells were then transduced with a viral vector encoding a CD19-specific CAR and differentiated into highly cytotoxic T lymphocytes. In a mouse model of Burkitt's lymphoma, expanded, iPS cell–derived, CD19-specific CAR T lymphocytes conferred a survival advantage comparable to that of parent CD19-specific CAR T lymphocytes. Next steps include further optimization of the method for generating iPS cell–derived, CAR-expressing T cells for autologous or allogeneic therapies. *SciBX* 6(36); doi:10.1038/scibx.2013.1014 Published online Sept. 19, 2013	Patent application filed; available for licensing	Themeli, M. *et al. Nat. Biotechnol.*; published online Aug. 11, 2013; doi:10.1038/nbt.2678 **Contact:** Michel Sadelain, Memorial Sloan-Kettering Cancer Center, New York, N.Y. e-mail: sadelaim@mskcc.org